Neoleukin Therapeutics Inc. (NASDAQ: NLTX)’s -20.32% Loss This Week Just Tells Us Something New – Marketing Sentinel
Home  »  Company   »  Neoleukin Therapeutics Inc. (NASDAQ: NLTX)’s -20...

Neoleukin Therapeutics Inc. (NASDAQ: NLTX)’s -20.32% Loss This Week Just Tells Us Something New

During the last session, Neoleukin Therapeutics Inc. (NASDAQ:NLTX)’s traded shares were 0.51 million, with the beta value of the company hitting 1.23. At the end of the trading day, the stock’s price was $0.98, reflecting an intraday loss of -8.40% or -$0.09. The 52-week high for the NLTX share is $11.52, that puts it down -1075.51 from that peak though still a striking -4.08% loss since the share price plummeted to a 52-week low of $1.02. The company’s market capitalization is $44.38M, and the average trade volume was 280.86K shares over the past three months.

Neoleukin Therapeutics Inc. (NLTX) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.40. NLTX has a Sell rating from 0 analyst(s) out of 6 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 6 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.3.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Neoleukin Therapeutics Inc. (NASDAQ:NLTX) trade information

Neoleukin Therapeutics Inc. (NLTX) registered a -8.40% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -8.40% in intraday trading to $0.98 this Friday, 05/13/22, hitting a weekly high. The stock’s 5-day price performance is -20.32%, and it has moved by -30.98% in 30 days. Based on these gigs, the overall price performance for the year is -91.26%.

The consensus price target of analysts on Wall Street is $17.00, which implies an increase of 94.24% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6.00 and $25.00 respectively. As a result, NLTX is trading at a discount of -2451.02% off the target high and -512.24% off the low.

Neoleukin Therapeutics Inc. (NLTX) estimates and forecasts

Statistics show that Neoleukin Therapeutics Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Neoleukin Therapeutics Inc. (NLTX) shares have gone down -84.66% during the last six months, with a year-to-date growth rate less than the industry average at -12.73% against -0.10. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to shrink -11.10% this quarter and then drop -7.10% in the quarter after that.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 10.90%. While earnings are projected to return -71.70% in 2022, the next five years will return 31.10% per annum.

NLTX Dividends

Neoleukin Therapeutics Inc. is due to release its next quarterly earnings between August 03 and August 08. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Neoleukin Therapeutics Inc. (NASDAQ:NLTX)’s Major holders

Neoleukin Therapeutics Inc. insiders own 21.48% of total outstanding shares while institutional holders control 58.99%, with the float percentage being 75.14%. Baker Brothers Advisors, LLC is the largest shareholder of the company, while 128 institutions own stock in it. As of Dec 30, 2021, the company held over 3.82 million shares (or 8.99% of all shares), a total value of $18.42 million in shares.

The next largest institutional holding, with 3.49 million shares, is of Redmile Group, LLC’s that is approximately 8.21% of outstanding shares. At the market price on Dec 30, 2021, these shares were valued at $16.83 million.

Also, the Mutual Funds coming in first place with the largest holdings of Neoleukin Therapeutics Inc. (NLTX) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. Data provided on Dec 30, 2021 indicates that Vanguard Total Stock Market Index Fund owns about 0.9 million shares. This amounts to just over 2.13 percent of the company’s overall shares, with a $4.36 million market value. The same data shows that the other fund manager holds slightly less at 0.81 million, or about 1.90% of the stock, which is worth about $2.89 million.

Leave a Comment

Your email address will not be published.

On Key

Related Posts